KR860008202A - 신규한 히알루론산염의 제조방법 - Google Patents

신규한 히알루론산염의 제조방법 Download PDF

Info

Publication number
KR860008202A
KR860008202A KR1019860002595A KR860002595A KR860008202A KR 860008202 A KR860008202 A KR 860008202A KR 1019860002595 A KR1019860002595 A KR 1019860002595A KR 860002595 A KR860002595 A KR 860002595A KR 860008202 A KR860008202 A KR 860008202A
Authority
KR
South Korea
Prior art keywords
hyaluronic acid
sulfate
salt
molecular weight
equivalent number
Prior art date
Application number
KR1019860002595A
Other languages
English (en)
Other versions
KR910006810B1 (ko
Inventor
델라 발레 프란세스코
델라발레 프란세스코
로메오 아우렐리오
로메오 아우텔리오
로렌지 실바나
Original Assignee
피디아 에스. 피. 에이.
델라 발레 프란세스코
피디아 에스. 피. 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR860008202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IT48980/85A external-priority patent/IT1184675B/it
Application filed by 피디아 에스. 피. 에이., 델라 발레 프란세스코, 피디아 에스. 피. 에이 filed Critical 피디아 에스. 피. 에이.
Publication of KR860008202A publication Critical patent/KR860008202A/ko
Application granted granted Critical
Publication of KR910006810B1 publication Critical patent/KR910006810B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

내용 없음

Description

신규한 히알루론산염의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 히알루론산바륨염의 수용액을 약리학적 활성물질의 황산염과 배합시킨 다음 침전된 황산바륨을 분리해 내어 히알루론산염 수용액이 얻어지도록 하므로써 히알루론산염을 제조하는 방법.
  2. 제1항에 있어서, 상기 황산염은 황산염의 등가수가 히알루론산등가수와 같은 양이되도록 첨가시키므로서 화학양론적으로 중성인 히알루론산염이 얻어지도록하는 방법.
  3. 제1항에 있어서, 상기 황산염은 황산염의 등가수가 히알루론산등가수와 적은 양이되도록 첨가시키므로서 부분적으로 염화(鹽化)된 히알루론산염이 얻어지도록하는 방법.
  4. 제1항에 있어서, 히알루론산바륨염은 알카리나 알카리토금속, 알루미늄 또는 암모늄중에서 선택된 적어도 하나 이상의 황산염과 추가로 배합되어지는 방법.
  5. 제4항에 있어서, 상기 황산염은 황산염의 등가수가 히알루론산등가수와 같은 양이 되도록 첨가되어지는 방법.
  6. 제4항에 있어서, 상기 황산염은 황산염의 등가수가 히알루론산 등가수보다 적은 양이 되도록 첨가되어지는 방법.
  7. 제1항에 있어서, 상기 활성물질은 항생제나 항감염제, 항균제, 항바이러스제, 세포성색전증, 항종양제, 소염제, 상처치유제, 마취제, 콜린효능촉진제, 콜린길항제, 아드레날린 효능촉진제 및 아드레날린길항제중에서 선택된 적어도 하나이상의 물질로되어진 것인 방법.
  8. 제1항에 있어서, 상기 활성물질은 에리스토마이신이나 겐타마이신, 네오마이신, 스트렙토마이신, 디하이드로스트렙토마이신, 가나마이신, 아미카신, 토브라마이신, 오레오마이신, 스펙티노마이신, 오리엔도마이신, 카보마이신, 스피타마이신, 옥시테트라싸이클린, 로리테트라싸이클린, 바시트라신, 폴리믹신B, 그라미신딘, 콜리스틴, 클로람페니콜, 린코마이신, 암모테리신B, 그리세오플빈, 니스타틴, 디에틸카바미진, 메벤다졸, 설파아세트아미드, 설파디아진, 설프이속사졸, 요오드옥시유리딘, 아데닌아라비노시드, 트리카핀, 메타콜린, 카바밀콜린, 아세클리딘, 피소스티그민, 네오스티그민, 데마카리움, 스트로피나, 프로파노롤티모롤, 핀도롤, 부프라노롤, 아테노롤, 메토프로롤, 옥스프레노롤, 프락토롤, 부톡사민, 소타롤, 부타드린, 라베타롤, 덱사메타손, 트리암시노론, 프레드니소론, 플루오로메토론 및 메드리손중에서 선택된 적어도 하나 이상의 물질로 되어진것인 방법.
  9. 제1항, 제2항, 제3항, 제4항, 제5항, 제6항중 어느 하나의 항에 있어서, 히알루론산은 분자량이 13,000,000인 히알루론산의 분자량에 대해 90~80% 내지 0.23%에 해당하는 만큼의 분자량을 갖는 히알루론산 분자분획물인 것.
  10. 제9항에 있어서, 히알루론산분자분획물은 분자량이 30,000이하인 히알루론산이 실제로 유리되어져서 함유되어 있지 않은 것.
  11. 제10항에 있어서, 히알루론산 분자분획물은 평균분자량이 약 50,000~100,000이나 약 500,000~730,000 또는 약 250,000~350,000인 것.
  12. 히알루론산 또는 그 분자분획물의 세틸피리디늄염을 염화바륨수용액으로 처리시킨다음, 수용액을 분리해내고 에탄올을 첨가시켜서 히알루론산 또는 그 분자분획물의 바륨염을 제조하는 방법.
  13. 제12항에 있어서, 히알루론산 분자분획물은 분자량이 30,000이하인 히알루론산이 실제로 유리되어져서 함유되어 있지 않은 것인 방법.
  14. 제13항에 있어서, 히알루론산 분자분획물은 평균분자량이 약 50,000~100,000이나 약 500,000~730,000 또는 약 250,000~350,000인 것.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860002595A 1985-04-05 1986-04-04 신규한 히알루론산염의 제조방법 KR910006810B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IT8547924A IT1229075B (it) 1985-04-05 1985-04-05 Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
IT47924-A/85 1985-04-05
IT47924A85 1985-04-05
CN85102921A CN85102921B (zh) 1985-04-05 1985-04-09 制备具有药物作用的透明质酸组份及含该组份的药物的方法
IT48980-A/85 1985-12-23
IT48980/85A IT1184675B (it) 1985-12-23 1985-12-23 Procedimento per la preparazione di sali dell'acido ialuronico
IT48980A85 1985-12-23

Publications (2)

Publication Number Publication Date
KR860008202A true KR860008202A (ko) 1986-11-12
KR910006810B1 KR910006810B1 (ko) 1991-09-02

Family

ID=36694284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860002595A KR910006810B1 (ko) 1985-04-05 1986-04-04 신규한 히알루론산염의 제조방법

Country Status (27)

Country Link
US (1) US4736024A (ko)
EP (2) EP0555898A3 (ko)
JP (2) JP2585216B2 (ko)
KR (1) KR910006810B1 (ko)
CN (1) CN85102921B (ko)
AR (1) AR245369A1 (ko)
AT (1) ATE98495T1 (ko)
AU (1) AU592077B2 (ko)
BE (1) BE904547A (ko)
CA (2) CA1340825C (ko)
CH (1) CH672886A5 (ko)
DE (1) DE3689384T3 (ko)
DK (1) DK149886A (ko)
ES (1) ES8800055A1 (ko)
FI (1) FI83966C (ko)
FR (1) FR2579895B1 (ko)
HU (1) HU204202B (ko)
IE (1) IE64440B1 (ko)
IL (1) IL78263A0 (ko)
IN (1) IN165867B (ko)
IT (1) IT1229075B (ko)
LU (1) LU86386A1 (ko)
NO (1) NO174277C (ko)
NZ (1) NZ215676A (ko)
PH (1) PH29979A (ko)
PT (1) PT82342B (ko)
ZA (1) ZA862463B (ko)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1186772B (it) * 1985-10-10 1987-12-16 Crinos Industria Farmaco Composto ad attivita' pilostimolante
EP0259485A4 (en) * 1986-03-14 1988-07-29 Bio Technology General Corp HEAVY METAL SALTS OF HYALURONIC ACID FOR USE AS AN ANTIMICROBIAL AGENT.
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
WO1988007060A1 (en) * 1987-03-19 1988-09-22 Arthropharm Pty. Limited Anti-inflammatory compounds and compositions
DE3864188D1 (de) * 1987-05-20 1991-09-19 Ueno Seiyaku Oyo Kenkyujo Kk Kondom.
EP0297860B1 (en) * 1987-07-01 1993-09-01 Genentech, Inc. Method and therapeutic compositions for the prevention of fibrin deposition or adhesions
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
JPH01213227A (ja) * 1988-02-23 1989-08-28 Tadashi Koyake 軟膏剤及び液剤
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
JPH0232013A (ja) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk 点鼻剤
JPH02200624A (ja) * 1989-01-30 1990-08-08 Nippon Kayaku Co Ltd 歯科用包帯剤
US6458774B1 (en) * 1989-02-24 2002-10-01 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing hyaluronic acid associates and a process for preparing same
HU203372B (en) * 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
US5472950A (en) * 1989-02-24 1995-12-05 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing cobalt hyaluronic acid complex
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP2945993B2 (ja) * 1989-12-05 1999-09-06 武田薬品工業株式会社 外用剤
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
NL8903155A (nl) * 1989-12-23 1991-07-16 Stamicarbon Harssamenstelling op basis van een polyesterhars, een aminohars en een epoxyhars.
AU7312291A (en) * 1990-02-13 1991-09-03 Gere S. Dizerega Peritoneal induced medicaments
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5492936A (en) * 1990-11-30 1996-02-20 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
AU3658793A (en) * 1992-02-10 1993-09-03 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6136793A (en) * 1992-02-20 2000-10-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
IT1263144B (it) * 1993-02-04 1996-08-01 Lanfranco Callegaro Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive
IL108808A (en) * 1993-03-04 1996-09-12 Genzyme Ltd Controlled lowering of molecular weight of polymers
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
JP4010574B2 (ja) * 1994-12-05 2007-11-21 電気化学工業株式会社 皮膚外用剤
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
IT1287227B1 (it) 1996-04-04 1998-08-04 Fidia Spa In Amministrazione S Acido ialuronico quale componente del liquido di conservazione della cornea
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6451326B2 (en) 1996-05-02 2002-09-17 Burt D. Ensley Cosmetic compositions
HU225991B1 (en) * 1997-04-29 2008-02-28 Richter Gedeon Nyrt Use of the zinc hyaluronate associate (complex) for the preparation of pharmaceutical compositions for oral use against peptic ulcer
IT1287967B1 (it) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
US5843186A (en) * 1996-12-20 1998-12-01 Implemed, Inc. Intraocular lens with antimicrobial activity
US5789571A (en) * 1997-01-15 1998-08-04 Biocoat Incorporated Method of making free acids from polysaccharide salts
US20050090662A1 (en) * 1997-01-15 2005-04-28 Beavers Ellington M. Method of making free acids from polysaccharide salts
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2285542C (en) * 1997-04-04 2007-07-17 Fidia Advanced Biopolymers Srl N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
DE69833665T2 (de) * 1997-08-08 2006-11-09 Duke University Zusammensetzungen zur vereinfachung von chirurgischen verfahren
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
JP2002193830A (ja) * 1998-10-19 2002-07-10 High Chem Co Ltd 経鼻投与用医薬製剤
DK172900B1 (da) * 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
JP4790911B2 (ja) 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
WO2000044367A2 (en) * 1999-02-01 2000-08-03 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
WO2001091796A2 (en) 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
JP2004514702A (ja) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド 眼における移植拒絶を予防するための眼内インプラント
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
DK1429807T3 (da) * 2001-09-19 2007-06-18 Altana Pharma Ag Kombination af et NSAID og en PDE4-inhibitor
ITMI20021666A1 (it) * 2002-07-26 2004-01-26 Jasper Ltd Liability Co Derivati dell'acido ialuronico
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2005016386A1 (en) * 2003-08-19 2005-02-24 Meditech Research Limited Improved therapeutic protocols
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US7625581B2 (en) * 2003-12-19 2009-12-01 Ethicon, Inc. Tissue scaffolds for use in muscoloskeletal repairs
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
ES2318453T3 (es) 2004-01-20 2009-05-01 Allergan, Inc. Composiciones para terapia localizada del ojo, que comprenden, de preferencia,triamcinolona acetonida y acido hialuronico.
FR2865651B1 (fr) * 2004-01-29 2007-09-28 Fabre Pierre Dermo Cosmetique Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
GB0416397D0 (en) * 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
WO2006034383A1 (en) * 2004-09-21 2006-03-30 Advanced Medical Optics, Inc. Viscoelastic solution or gel formulation, and methods of treating a body site with the same
SE0402272D0 (sv) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
EP1721602A1 (en) * 2005-05-11 2006-11-15 The Jordanian Pharmaceutical Manufacturing Co. Controlled release oral drug delivery system
FR2888752B1 (fr) * 2005-07-22 2007-10-05 Fabre Pierre Dermo Cosmetique Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
AU2006274509B2 (en) * 2005-07-27 2012-01-19 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
US20070065515A1 (en) * 2005-09-22 2007-03-22 Key Douglas J Methods and compositions for treating skin lines and wrinkles and improving skin quality
JP4555232B2 (ja) * 2006-01-25 2010-09-29 Ｈｏｙａ株式会社 組織の蛍光染色方法
US8668676B2 (en) 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP2037874A1 (en) * 2006-06-28 2009-03-25 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic and medical uses
WO2008003321A2 (en) * 2006-07-07 2008-01-10 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic use
US20080097335A1 (en) 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
ES2621876T3 (es) 2006-09-13 2017-07-05 Enhance Skin Products Inc. Composición cosmética para el tratamiento de la piel y procedimientos de la misma
AU2008210557B2 (en) 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
EP2207424B1 (en) 2007-11-16 2014-06-04 Allergan, Inc. Compositions and methods for treating purpura
US20090306025A1 (en) * 2008-05-30 2009-12-10 Fairfield Clinical Trials, Llc Method and composition for skin inflammation and discoloration
WO2010003797A1 (en) * 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Hyaluronic acid for corneal wound healing
CA2739243C (en) 2008-10-02 2017-08-22 L.R.R.& D. Ltd. Wound dressing comprising polymeric foam matrix and a hydrophilic polysaccharide disposed therein
CN101385874B (zh) * 2008-10-23 2012-11-28 武汉大学 一种含有高分子透明质酸的生物滑液的制备方法
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
JP2012526819A (ja) * 2009-05-11 2012-11-01 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド 脂質−ポリマー複合体、その調製、及びその使用
TWI383796B (zh) 2009-08-14 2013-02-01 Holy Stone Healthcare Co Ltd Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
TWI516269B (zh) 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
IT1407283B1 (it) * 2010-12-06 2014-04-04 Paoli Ambrosi De Nuovo composto di carnosina
CZ303548B6 (cs) 2011-01-05 2012-11-28 Contipro Pharma A.S. Zdravotní prípravek tvorící jód, zpusob jeho prípravy a bandáž, která jej obsahuje
CZ22394U1 (cs) 2011-03-11 2011-06-20 Contipro C, A.S. Antimikrobiální smes a kryt pro podporu hojení ran s antimikrobiálním úcinkem
DK2543357T3 (en) 2011-07-07 2018-07-02 Holy Stone Healthcare Co Ltd COMPOSITION FOR USE FOR TREATMENT AND PREVENTION OF INFLAMMATION-RELATED DISORDERS
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
ITMI20111747A1 (it) 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
JP2014141475A (ja) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd 新規美白剤
KR101412776B1 (ko) 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 각결막염 치료용 점안제 조성물 및 이의 제조 방법
CN103319627A (zh) * 2013-07-10 2013-09-25 南宁中诺生物工程有限责任公司 一种对透明质酸钠进行分子量分级的方法
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
EP3104851A1 (en) * 2014-02-11 2016-12-21 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
US9603867B2 (en) * 2015-03-03 2017-03-28 Yung Shin Pharm. Ind. Co., Ltd. Pharmaceutical composition for improving wound healing or prophylactically preventing or inhibiting scar formation
ITUB20152542A1 (it) * 2015-07-28 2017-01-28 Altergon Sa Formulati oftalmici a base di complessi cooperativi di acido ialuronico a basso e alto peso molecolare
WO2017138626A1 (ja) 2016-02-12 2017-08-17 株式会社らいむ 神経伸長促進剤とその製造方法、内服剤、培地用添加剤、細胞希釈液用添加剤、培地、細胞希釈液、抗酸化剤とその製造方法、外用剤、および創傷治療剤とその製造方法
CA3031370A1 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
CN106727246A (zh) * 2017-02-08 2017-05-31 上海元茵生物科技有限公司 小牛血清细胞营养液
CN107802597B (zh) * 2017-12-08 2020-07-31 北京诺康达医药科技股份有限公司 一种玻璃酸钠组合物及其制备方法和应用
MA51612B1 (fr) * 2018-01-18 2021-06-30 Faes Farma Sa Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant
FR3086865B1 (fr) * 2018-10-04 2023-04-28 Matthieu Leconte Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
DE1047380B (de) * 1954-08-18 1958-12-24 American Home Prod Verfahren zur Herstellung einer hyaluronidasefreien, teilweise depolymerisierte Hyaluronsaeure enthaltenden waessrigen Traegerloesung fuer Arzneimittel
GB818336A (en) * 1956-06-22 1959-08-12 Erba Carlo Spa A new acid aminopolysaccharide and a process for the production thereof
FR1425265A (fr) * 1962-05-14 1966-01-24 Parke Davis & Co Procédé de préparation d'un nouveau polysaccharide et de ses sels
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
US3792164A (en) * 1970-03-31 1974-02-12 Chemway Corp Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US3936081A (en) * 1974-02-27 1976-02-03 R & G Sloane Manufacturing Co., Inc. Pipe joint and method of making same
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
HU172937B (hu) * 1975-12-18 1979-01-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh khondroitin-sernoj kisloty s mestno anestezirujuhhim ehffektom
SE7901565L (sv) * 1979-02-21 1980-08-22 Pharmacia Ab Medel for immunisering
JPS55153711A (en) * 1979-05-19 1980-11-29 Pola Chem Ind Inc Cosmetic lotion
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4359458A (en) * 1981-09-28 1982-11-16 American Cyanamid Company O-β. -D (and O-α.. -D) Multigalactopyranosyl, xylopyranosyl and glucopyranosyl sulfate salts
JPS591405A (ja) * 1982-06-28 1984-01-06 Shiseido Co Ltd 乳化組成物
JPS597106A (ja) * 1982-07-06 1984-01-14 Shiseido Co Ltd 乳化組成物
JPS5920212A (ja) * 1982-07-27 1984-02-01 Shiseido Co Ltd 乳化組成物
JPS5939338A (ja) * 1982-08-30 1984-03-03 Shiseido Co Ltd 乳化組成物
IT1212892B (it) * 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
JPS59219209A (ja) * 1983-05-28 1984-12-10 Kanebo Ltd 皮膚化粧料
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
DE3461292D1 (en) * 1983-08-12 1987-01-02 Ciba Geigy Ag Monoclinic lead chromate pigments
DE3334595A1 (de) * 1983-09-24 1985-04-18 B. Braun Melsungen Ag, 3508 Melsungen Wirkstoffdepot
CH666897A5 (fr) * 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
JPS61180723A (ja) * 1985-02-06 1986-08-13 Sanwa Kagaku Kenkyusho:Kk 易吸収性カリジノゲナ−ゼ製剤用組成物
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
AU7312291A (en) * 1990-02-13 1991-09-03 Gere S. Dizerega Peritoneal induced medicaments

Also Published As

Publication number Publication date
IT1229075B (it) 1991-07-17
NO174277B (no) 1994-01-03
IL78263A0 (en) 1986-07-31
DK149886A (da) 1986-10-06
ES8800055A1 (es) 1987-11-16
PH29979A (en) 1996-10-29
JP2585216B2 (ja) 1997-02-26
EP0197718A3 (en) 1987-09-09
JPH09169667A (ja) 1997-06-30
DE3689384T3 (de) 2003-05-15
EP0555898A2 (en) 1993-08-18
DE3689384D1 (de) 1994-01-27
PT82342A (en) 1986-05-01
BE904547A (fr) 1986-10-03
CA1341418C (en) 2003-01-21
AU592077B2 (en) 1990-01-04
EP0197718A2 (en) 1986-10-15
CA1340825C (en) 1999-11-23
AR245369A1 (es) 1994-01-31
NO861331L (no) 1986-10-06
KR910006810B1 (ko) 1991-09-02
HUT40579A (en) 1987-01-28
CN85102921B (zh) 1988-06-08
FR2579895B1 (ko) 1990-11-23
IE64440B1 (en) 1995-08-09
JP2677778B2 (ja) 1997-11-17
AU5566286A (en) 1986-10-16
DE3689384T2 (de) 1994-07-07
IT8547924A0 (it) 1985-04-05
FI83966C (fi) 1991-09-25
ZA862463B (en) 1987-12-30
DK149886D0 (da) 1986-04-02
ATE98495T1 (de) 1994-01-15
FI83966B (fi) 1991-06-14
IE860847L (en) 1986-10-05
NO174277C (no) 1994-04-13
EP0197718B1 (en) 1993-12-15
CH672886A5 (ko) 1990-01-15
FI861395A (fi) 1986-10-06
HU204202B (en) 1991-12-30
FR2579895A1 (ko) 1986-10-10
CN85102921A (zh) 1986-10-08
JPS61236732A (ja) 1986-10-22
FI861395A0 (fi) 1986-04-01
ES553714A0 (es) 1987-11-16
EP0197718B2 (en) 2001-07-25
EP0555898A3 (en) 1993-10-20
US4736024A (en) 1988-04-05
IN165867B (ko) 1990-02-03
LU86386A1 (fr) 1986-09-02
NZ215676A (en) 1989-08-29
PT82342B (pt) 1988-03-03

Similar Documents

Publication Publication Date Title
KR860008202A (ko) 신규한 히알루론산염의 제조방법
DE2642837C3 (de) Anthracyclinglycoside und Verfahren zu deren Herstellung
KR910000771A (ko) 새로운 헤파린 유도체 및 그 제조방법
DE69419447D1 (de) Salbe zur Wundbehandlung
SU1169543A3 (ru) Способ получени аналогов линкомицина и клиндамицина
JP2019521151A (ja) ダパグリフロジン中間体の結晶形及びその製造方法
DE1618857A1 (de) Verfahren zur Herstellung von Chondroitinpolysulfat
DE2515630C2 (de) 4-0-(6-Amino-6-desoxy-alpha-D-glucopyranosyl)-5-0[3-0(2,6-diamino-2,6-didesoxy-ß-L-idophyranosyl)-ß-D-ribofuranosyl]-2-desoxy-streptamin, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel
Kapadia et al. Revised structure of paederoside, a novel monoterpene S-methyl thiocarbonate
KR880009010A (ko) 신규한 테트라히드로 푸란의 5-옥시 유도체의 제조방법
CH626896A5 (ko)
US3386921A (en) Gels and methods of producing same
EP3373975B1 (de) Dialyselösung mit wenigstens einem osmotikum
DE1542832A1 (de) Fluessigkeit zum Einstellen von Schnittblumen,abgeschnittenen Pflanzenteilen usw.
DE1270275B (de) Stabilisierung von Polyurethanen
SIDAMONIDZE et al. HYDROSULPHURISATION REACTIONS OF ALLYL DERIVATIVES OF ALTROPYRANOSE WITH MERCAPTANS.
DE932670C (de) Verfahren zur Herstellung von Tetracyclin und seinen Salzen
ATE32212T1 (de) Verfahren zur herstellung von 4hydroxybenzophenonen.
KR900700385A (ko) 결정성 분자체의 합성방법
RU2021107503A (ru) Хлорированное производное гиалуроновой кислоты, способ его получения, содержащая производное композиция и ее применение
Marvel et al. A Twenty-six-membered Cyclic Dimercaptal1
EP0036554A2 (de) Diagnostisches Mittel zum Nachweis von Keton-Körpern
DE2752532C3 (de) Verfahren zur Herstellung von 2-Brom- a -ergokryptin
DE2723417C3 (de) 5,6-Epineamin und dessen Verwendung bei der Bekämpfung bakterieller Infektionen
Pacsu et al. Studies in the Ketone Sugar Series. V. The Validity of Hudson's Rules of Isorotation in the Ketose Group. Preparation of the True α-Pentaacetylfructose< 2, 6>

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050824

Year of fee payment: 15

EXPY Expiration of term